The Tuberculosis (TB) Treatment market was valued at US$ xx in 2023. The market for Tuberculosis (TB) Treatment is projected to grow from US$ xx million in 2024, and is projected to reach xx by 2031, at a CAGR of xx% during the forecast period. Projected and forecast revenue values are in constant U.S. dollars, unadjusted for inflation. Product values are estimated based on manufacturers' revenue. The report offers detailed coverage of Tuberculosis (TB) Treatment industry and main market trends. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Tuberculosis (TB) Treatment by geography. The report splits the market size, by volume and value, on the basis of application type and geography. In addition to this data, the report provides insight into drivers of market demand and strategies of suppliers. Key players are profiled, and their market shares in the global Tuberculosis (TB) Treatment market are discussed. The market is segmented by types: Isoniazid Rifampin (Rifadin, Rimactane) Ethambutol (Myambutol) Pyrazinamide It can be also divided by applications: Active TB Latent TB And this report covers the historical situation, present status and the future prospects of the global Tuberculosis (TB) Treatment market for 2021-2031. In this report, we analyze global market from 5 geographies: Asia-Pacific, Europe, North America, Middle East & Africa, South America. Finally, the report provides detailed profile and data information analysis of leading company. Johnson & Johnson Sanofi Dong-A ST Co., Ltd Otsuka Pharmaceutical Co., Ltd Mylan Macleods Pharmaceutical Ltd Johnson & Johnson Lupin Ltd Report Includes: - xx data tables and xx additional tables - An overview of global Tuberculosis (TB) Treatment market - An detailed key players analysis across regions - Analyses of global market trends, with historical data, estimates for 2024 and projections of compound annual growth rates (CAGRs) through 2031 - Insights into regulatory and environmental developments - Information on the supply and demand scenario and evaluation of technological and investment opportunities in the Tuberculosis (TB) Treatment market - Profiles of major players in the industry, including Johnson & Johnson, Sanofi, Dong-A ST Co., Ltd, Otsuka Pharmaceutical Co., Ltd, Mylan..... Research objectives To study and analyze the global Tuberculosis (TB) Treatment consumption (value & volume) by key regions/countries, product type and application, history data from 2019 to 2021, and Forecast to 2031. To understand the structure of Tuberculosis (TB) Treatment market by identifying its various subsegments. Focuses on the key global Tuberculosis (TB) Treatment manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, Porter's five forces analysis, SWOT analysis and development plans in next few years. To analyze the Tuberculosis (TB) Treatment with respect to individual growth trends, future prospects, and their contribution to the total market. To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks). To project the consumption of Tuberculosis (TB) Treatment submarkets, with respect to key regions (along with their respective key countries). To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market. To strategically profile the key players and comprehensively analyze their growth strategies.
Table of Contents Global Tuberculosis (TB) Treatment Market Report 2024, Forecast to 2031 1 Scope of the Study 1.1 Tuberculosis (TB) Treatment Introduction 1.2 Research Programs 1.3 Analysis of Macroeconomic Indicators 1.4 Years Considered 1.5 Methodology 1.6 Data Source 1.7 Research Objectives 2 Tuberculosis (TB) Treatment Industry Overview 2.1 Global Tuberculosis (TB) Treatment Market Size (Million USD) Comparison by Regions (2024-2031) 2.1.1 Tuberculosis (TB) Treatment Global Main Region Market Analysis 2.2 Market Analysis by Type 2.2.1 Isoniazid 2.2.2 Rifampin (Rifadin, Rimactane) 2.2.3 Ethambutol (Myambutol) 2.2.4 Pyrazinamide 2.3 Market Analysis by Application 2.3.1 Active TB 2.3.2 Latent TB 2.4 Global Tuberculosis (TB) Treatment Revenue, Sales and Market Share by Manufacturer 2.4.1 Global Tuberculosis (TB) Treatment Sales and Market Share by Manufacturer (2019-2023) 2.4.2 Global Tuberculosis (TB) Treatment Revenue and Market Share by Manufacturer (2019-2023) 2.4.3 Global Tuberculosis (TB) Treatment Industry Concentration Ratio (CR5 and HHI) 2.4.4 Top 5 Tuberculosis (TB) Treatment Manufacturer Market Share 2.4.5 Top 10 Tuberculosis (TB) Treatment Manufacturer Market Share 2.4.6 Date of Key Manufacturers Enter into Tuberculosis (TB) Treatment Market 2.4.7 Key Manufacturers Tuberculosis (TB) Treatment Product Offered 2.4.8 Mergers & Acquisitions Planning 2.5 Tuberculosis (TB) Treatment Historical Development Overview 2.6 Market Dynamics 2.6.1 Market Opportunities 2.6.2 Market Risk 2.6.3 Market Driving Force 2.6.4 Porter's Five Forces Analysis 2.7 Coronavirus Disease 2019 (Covid-19): Tuberculosis (TB) Treatment Industry Impact 2.7.1 How the Covid-19 is Affecting the Tuberculosis (TB) Treatment Industry 2.7.2 Tuberculosis (TB) Treatment Business Impact Assessment - Covid-19 2.7.3 Market Trends and Tuberculosis (TB) Treatment Potential Opportunities in the COVID-19 Landscape 2.7.4 Measures / Proposal against Covid-19 3 Related Market Analysis 3.1 Related Market Overview 3.2 Macro Analysis of Upstream Markets 3.3 Key Players in Related Markets 3.4 Related Markets Trend Analysis 4 Global Tuberculosis (TB) Treatment Market Size Categorized by Regions 4.1 Global Tuberculosis (TB) Treatment Revenue and Market Share by Regions 4.1.1 Global Tuberculosis (TB) Treatment Sales and Market Share by Regions (2019-2023) 4.1.2 Global Tuberculosis (TB) Treatment Revenue and Market Share by Regions (2019-2023) 4.2 Europe Tuberculosis (TB) Treatment Revenue and Growth Rate (2019-2023) 4.3 APAC Tuberculosis (TB) Treatment Revenue and Growth Rate (2019-2023) 4.4 North America Tuberculosis (TB) Treatment Revenue and Growth Rate (2019-2023) 4.5 South America Tuberculosis (TB) Treatment Revenue and Growth Rate (2019-2023) 4.6 Middle East & Africa Tuberculosis (TB) Treatment Revenue and Growth Rate (2019-2023) 5 Europe Tuberculosis (TB) Treatment Market Size Categorized by Countries 5.1 Europe Tuberculosis (TB) Treatment Revenue and Market Share by Countries 5.1.1 Europe Tuberculosis (TB) Treatment Revenue by Countries (2019-2023) 5.1.2 Germany Tuberculosis (TB) Treatment Revenue and Growth Rate (2019-2023) 5.1.3 UK Tuberculosis (TB) Treatment Revenue and Growth Rate (2019-2023) 5.1.4 France Tuberculosis (TB) Treatment Revenue and Growth Rate (2019-2023) 5.1.5 Russia Tuberculosis (TB) Treatment Revenue and Growth Rate (2019-2023) 5.1.6 Italy Tuberculosis (TB) Treatment Revenue and Growth Rate (2019-2023) 5.1.7 Spain Tuberculosis (TB) Treatment Revenue and Growth Rate (2019-2023) 5.2 Europe Tuberculosis (TB) Treatment Revenue (Value) by Manufacturers (2019-2023) 5.3 Europe Tuberculosis (TB) Treatment Revenue and Market Share by Type (2019-2023) 5.4 Europe Tuberculosis (TB) Treatment Revenue and Market Share by Application (2019-2023) 6 Asia-Pacific Tuberculosis (TB) Treatment Market Size Categorized by Countries 6.1 Asia-Pacific Tuberculosis (TB) Treatment Revenue and Market Share by Countries 6.1.1 Asia-Pacific Tuberculosis (TB) Treatment Revenue by Countries (2019-2023) 6.1.2 China Tuberculosis (TB) Treatment Revenue and Growth Rate (2019-2023) 6.1.3 Japan Tuberculosis (TB) Treatment Revenue and Growth Rate (2019-2023) 6.1.4 Korea Tuberculosis (TB) Treatment Revenue and Growth Rate (2019-2023) 6.1.5 India Tuberculosis (TB) Treatment Revenue and Growth Rate (2019-2023) 6.1.6 Southeast Asia Tuberculosis (TB) Treatment Revenue and Growth Rate (2019-2023) 6.1.7 Australia Tuberculosis (TB) Treatment Revenue and Growth Rate (2019-2023) 6.2 Asia-Pacific Tuberculosis (TB) Treatment Revenue (Value) by Players (2019-2023) 6.3 Asia-Pacific Tuberculosis (TB) Treatment Revenue and Market Share by Type (2019-2023) 6.4 Asia-Pacific Tuberculosis (TB) Treatment Revenue and Market Share by Application (2019-2023) 7 North America Tuberculosis (TB) Treatment Market Size Categorized by Countries 7.1 North America Tuberculosis (TB) Treatment Revenue and Market Share by Countries 7.1.1 North America Tuberculosis (TB) Treatment Revenue by Countries (2019-2023) 7.1.2 United States Tuberculosis (TB) Treatment Revenue and Growth Rate (2019-2023) 7.1.3 Canada Tuberculosis (TB) Treatment Revenue and Growth Rate (2019-2023) 7.1.4 Mexico Tuberculosis (TB) Treatment Revenue and Growth Rate (2019-2023) 7.2 North America Tuberculosis (TB) Treatment Revenue (Value) by Players (2019-2023) 7.3 North America Tuberculosis (TB) Treatment Revenue and Market Share by Type (2019-2023) 7.4 North America Tuberculosis (TB) Treatment Revenue and Market Share by Application (2019-2023) 8 South America Tuberculosis (TB) Treatment Market Size Categorized by Countries 8.1 South America Tuberculosis (TB) Treatment Revenue and Market Share by Countries 8.1.1 South America Tuberculosis (TB) Treatment Revenue by Countries (2019-2023) 8.1.2 Brazil Tuberculosis (TB) Treatment Revenue and Growth Rate (2019-2023) 8.2 South America Tuberculosis (TB) Treatment Revenue (Value) by Players (2019-2023) 8.3 South America Tuberculosis (TB) Treatment Revenue and Market Share by Type (2019-2023) 8.4 South America Tuberculosis (TB) Treatment Revenue and Market Share by Application (2019-2023) 9 Middle East and Africa Tuberculosis (TB) Treatment Market Size Categorized by Countries 9.1 Middle East and Africa Tuberculosis (TB) Treatment Revenue and Market Share by Countries 9.1.1 Middle East and Africa Tuberculosis (TB) Treatment Revenue by Countries (2019-2023) 9.1.2 GCC Countries Tuberculosis (TB) Treatment Revenue and Growth Rate (2019-2023) 9.1.3 Turkey Tuberculosis (TB) Treatment Revenue and Growth Rate (2019-2023) 9.1.4 Egypt Tuberculosis (TB) Treatment Revenue and Growth Rate (2019-2023) 9.1.5 South Africa Tuberculosis (TB) Treatment Revenue and Growth Rate (2019-2023) 9.2 Middle East and Africa Tuberculosis (TB) Treatment Revenue (Value) by Players (2019-2023) 9.3 Middle East and Africa Tuberculosis (TB) Treatment Revenue and Market Share by Type (2019-2023) 9.4 Middle East and Africa Tuberculosis (TB) Treatment Revenue and Market Share by Application (2019-2023) 10 Global Tuberculosis (TB) Treatment Market Segment by Type 10.1 Global Tuberculosis (TB) Treatment Revenue and Market Share by Type (2019-2023) 10.2 Global Tuberculosis (TB) Treatment Market Forecast by Type (2024-2031) 10.3 Isoniazid Revenue Growth Rate 10.4 Rifampin (Rifadin, Rimactane) Revenue Growth Rate 10.5 Ethambutol (Myambutol) Revenue Growth Rate 10.6 Pyrazinamide Revenue Growth Rate 11 Global Tuberculosis (TB) Treatment Market Segment by Application 11.1 Global Tuberculosis (TB) Treatment Revenue Market Share by Application (2019-2023) 11.2 Global Tuberculosis (TB) Treatment Market Forecast by Application (2024-2031) 11.3 Active TB Revenue Growth Rate (2015-2025) 11.4 Latent TB Revenue Growth Rate (2015-2025) 12 Market Forecast for Tuberculosis (TB) Treatment 12.1 Global Tuberculosis (TB) Treatment Market Size Forecast (2024-2031) 12.2 Tuberculosis (TB) Treatment Market Forecast by Regions (2024-2031) 12.3 Europe Tuberculosis (TB) Treatment Revenue Market Forecast (2024-2031) 12.4 APAC Tuberculosis (TB) Treatment Revenue Market Forecast (2024-2031) 12.5 North America Tuberculosis (TB) Treatment Revenue Market Forecast (2024-2031) 12.6 South America Tuberculosis (TB) Treatment Revenue Market Forecast (2024-2031) 12.7 Middle East & Africa Tuberculosis (TB) Treatment Revenue Market Forecast (2024-2031) 13 Analysis of Tuberculosis (TB) Treatment Industry Key Vendors 13.1 Johnson & Johnson 13.1.1 Company Details 13.1.2 Product Information 13.1.3 Johnson & Johnson Tuberculosis (TB) Treatment Revenue and Gross Margin (2019-2023) 13.1.4 Main Business Overview 13.1.5 Johnson & Johnson News 13.2 Sanofi 13.2.1 Company Details 13.2.2 Product Information 13.2.3 Sanofi Tuberculosis (TB) Treatment Revenue and Gross Margin (2019-2023) 13.2.4 Main Business Overview 13.2.5 Sanofi News 13.3 Dong-A ST Co., Ltd 13.3.1 Company Details 13.3.2 Product Information 13.3.3 Dong-A ST Co., Ltd Tuberculosis (TB) Treatment Revenue and Gross Margin (2019-2023) 13.3.4 Main Business Overview 13.3.5 Dong-A ST Co., Ltd News 13.4 Otsuka Pharmaceutical Co., Ltd 13.4.1 Company Details 13.4.2 Product Information 13.4.3 Otsuka Pharmaceutical Co., Ltd Tuberculosis (TB) Treatment Revenue and Gross Margin (2019-2023) 13.4.4 Main Business Overview 13.4.5 Otsuka Pharmaceutical Co., Ltd News 13.5 Mylan 13.5.1 Company Details 13.5.2 Product Information 13.5.3 Mylan Tuberculosis (TB) Treatment Revenue and Gross Margin (2019-2023) 13.5.4 Main Business Overview 13.5.5 Mylan News 13.6 Macleods Pharmaceutical Ltd 13.6.1 Company Details 13.6.2 Product Information 13.6.3 Macleods Pharmaceutical Ltd Tuberculosis (TB) Treatment Revenue and Gross Margin (2019-2023) 13.6.4 Main Business Overview 13.6.5 Macleods Pharmaceutical Ltd News 13.7 Johnson & Johnson 13.7.1 Company Details 13.7.2 Product Information 13.7.3 Johnson & Johnson Tuberculosis (TB) Treatment Revenue and Gross Margin (2019-2023) 13.7.4 Main Business Overview 13.7.5 Johnson & Johnson News 13.8 Lupin Ltd 13.8.1 Company Details 13.8.2 Product Information 13.8.3 Lupin Ltd Tuberculosis (TB) Treatment Revenue and Gross Margin (2019-2023) 13.8.4 Main Business Overview 13.8.5 Lupin Ltd News 14 Research Findings and Conclusion 15 Appendix